Symbols / FHTX
FHTX Chart
About
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is also developing therapies for mutant cancers, such as androgen receptor, positive prostate cancer, bladder cancer, Non-Small Cell Lung (NSCLC), as well as various lymphomas and leukemias; melanoma, endometrial, gastric, breast, colorectal, and pancreatic cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 339.77M |
| Enterprise Value | 162.90M | Income | -72.12M | Sales | 24.52M |
| Book/sh | -1.59 | Cash/sh | 3.19 | Dividend Yield | — |
| Payout | 0.00% | Employees | 112 | IPO | — |
| P/E | — | Forward P/E | -5.91 | PEG | — |
| P/S | 13.86 | P/B | -3.66 | P/C | — |
| EV/EBITDA | -1.96 | EV/Sales | 6.64 | Quick Ratio | 2.12 |
| Current Ratio | 2.16 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -1.14 | EPS next Y | -0.98 | EPS Growth | — |
| Revenue Growth | 4.40% | Earnings | 2026-03-05 | ROA | -21.07% |
| ROE | — | ROIC | — | Gross Margin | -242.31% |
| Oper. Margin | -226.92% | Profit Margin | -294.16% | Shs Outstand | 58.58M |
| Shs Float | 27.49M | Short Float | 3.06% | Short Ratio | 6.17 |
| Short Interest | — | 52W High | 6.95 | 52W Low | 2.94 |
| Beta | 3.03 | Avg Volume | 168.05K | Volume | 138.40K |
| Target Price | $11.44 | Recom | Strong_buy | Prev Close | $5.67 |
| Price | $5.80 | Change | 2.29% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$11.44
Mean price target
2. Current target
$5.91
Latest analyst target
3. DCF / Fair value
$-3.19
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$5.91
Low
$9.00
High
$14.00
Mean
$11.44
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-17 | main | Jefferies | Buy → Buy | $12 |
| 2025-12-18 | init | BTIG | — → Buy | $11 |
| 2025-12-04 | init | Stifel | — → Buy | $12 |
| 2025-11-07 | init | Guggenheim | — → Buy | $12 |
| 2025-05-15 | reit | JMP Securities | Market Outperform → Market Outperform | $9 |
| 2025-04-30 | reit | JMP Securities | Market Outperform → Market Outperform | $9 |
| 2025-04-30 | reit | HC Wainwright & Co. | Buy → Buy | $13 |
| 2025-04-23 | init | JMP Securities | — → Market Outperform | $9 |
| 2025-03-07 | reit | HC Wainwright & Co. | Buy → Buy | $13 |
| 2025-01-30 | init | B. Riley Securities | — → Buy | $10 |
| 2024-12-17 | reit | HC Wainwright & Co. | Buy → Buy | $13 |
| 2024-12-16 | main | Jefferies | Buy → Buy | $14 |
| 2024-09-24 | main | Morgan Stanley | Equal-Weight → Equal-Weight | $9 |
| 2024-09-03 | init | Jefferies | — → Buy | $18 |
| 2024-08-19 | init | Evercore ISI Group | — → Outperform | $20 |
| 2024-08-12 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2024-08-09 | reit | Wedbush | Outperform → Outperform | $13 |
| 2024-05-07 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2024-05-01 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2024-04-10 | reit | Wedbush | Outperform → Outperform | $13 |
- Cancer-focused biotech Foghorn to present at two March investor forums - Stock Titan ue, 24 Feb 2026 12
- Foghorn Therapeutics Inc. Appoints Ryan Maynard as Chief Financial Officer - Quiver Quantitative Mon, 23 Feb 2026 12
- Foghorn Therapeutics Names Veteran Executive as New CFO - TipRanks Mon, 23 Feb 2026 12
- Biotech CFO who raised $1B in deals joins Foghorn Therapeutics - Stock Titan Mon, 23 Feb 2026 12
- Foghorn Therapeutics (FHTX): Forecast 28.8% Revenue Growth Challenges Ongoing Loss Narrative - Yahoo Finance Wed, 05 Nov 2025 08
- Jefferies Lowers Price Target for Foghorn Therapeutics (FHTX) to $12.00 | FHTX Stock News - GuruFocus ue, 17 Feb 2026 19
- Foghorn Therapeutics appoints interim CFO Jeff Sacher - MSN Mon, 16 Feb 2026 00
- Jefferies initiates Foghorn Therapeutics stock with buy rating By Investing.com - Investing.com Nigeria ue, 17 Feb 2026 13
- Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium - GlobeNewswire ue, 13 Jan 2026 08
- Here's Why We're Watching Foghorn Therapeutics' (NASDAQ:FHTX) Cash Burn Situation - simplywall.st Fri, 19 Dec 2025 08
- Foghorn Therapeutics (FHTX) Appoints New CFO with Extensive Expe - GuruFocus Mon, 23 Feb 2026 13
- Foghorn Therapeutics (FHTX) Upgraded to Buy: Here's Why - Yahoo Finance Mon, 25 Aug 2025 07
- Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) 26% Share Price Surge Not Quite Adding Up - 富途牛牛 Mon, 08 Sep 2025 07
- Foghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit - marketscreener.com ue, 03 Feb 2026 08
- Foghorn Therapeutics Announces $50 Million Equity Financing - TipRanks Mon, 12 Jan 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 300000 | — | — | Stock Gift at price 0.00 per share. | GOTTSCHALK ADRIAN | Chief Executive Officer | — | 2025-04-25 00:00:00 | I |
| 1 | 36613 | 367706 | — | Sale at price 10.04 - 10.17 per share. | COSTA CARLOS FERNANDO | Officer | — | 2024-09-23 00:00:00 | D |
| 2 | 36613 | 136200 | — | Conversion of Exercise of derivative security at price 3.72 per share. | COSTA CARLOS FERNANDO | Officer | — | 2024-09-23 00:00:00 | D |
| 3 | 11574 | 116319 | — | Sale at price 10.05 per share. | COSTA CARLOS FERNANDO | Officer | — | 2024-09-18 00:00:00 | D |
| 4 | 11574 | 43055 | — | Conversion of Exercise of derivative security at price 3.72 per share. | COSTA CARLOS FERNANDO | Officer | — | 2024-09-18 00:00:00 | D |
| 5 | 10672 | 107131 | — | Sale at price 10.00 - 10.04 per share. | COSTA CARLOS FERNANDO | Officer | — | 2024-09-17 00:00:00 | D |
| 6 | 10672 | 39700 | — | Conversion of Exercise of derivative security at price 3.72 per share. | COSTA CARLOS FERNANDO | Officer | — | 2024-09-17 00:00:00 | D |
| 7 | 20000 | 190000 | — | Sale at price 9.50 per share. | BELLON STEVEN F | Officer | — | 2024-09-09 00:00:00 | D |
| 8 | 11000 | 72134 | — | Sale at price 6.56 per share. | CAVALIE FANNY | Officer | — | 2024-03-11 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.21 | 0.00 | 0.00 |
| NormalizedEBITDA | -94.77M | -104.45M | -113.82M | -94.95M |
| TotalUnusualItems | -2.40M | 0.00 | 0.00 | -1.23M |
| TotalUnusualItemsExcludingGoodwill | -2.40M | 0.00 | 0.00 | -1.23M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -86.62M | -98.43M | -108.88M | -101.32M |
| ReconciledDepreciation | 3.12M | 3.45M | 3.32M | 3.23M |
| EBITDA | -97.17M | -104.45M | -113.82M | -96.19M |
| EBIT | -100.28M | -107.91M | -117.14M | -99.41M |
| NetInterestIncome | 11.90M | 10.88M | 5.67M | -1.85M |
| InterestExpense | 0.00 | 1.91M | ||
| InterestIncome | 11.90M | 10.88M | 5.67M | 59.00K |
| NormalizedIncome | -84.22M | -98.43M | -108.88M | -100.09M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -86.62M | -98.43M | -108.88M | -101.32M |
| TotalExpenses | 122.89M | 142.06M | 136.37M | 102.05M |
| TotalOperatingIncomeAsReported | -102.68M | -107.91M | -117.14M | -100.73M |
| DilutedAverageShares | 54.90M | 41.97M | 41.59M | 37.17M |
| BasicAverageShares | 54.90M | 41.97M | 41.59M | 37.17M |
| DilutedEPS | -1.58 | -2.34 | -2.62 | -2.73 |
| BasicEPS | -1.58 | -2.34 | -2.62 | -2.73 |
| DilutedNIAvailtoComStockholders | -86.62M | -98.43M | -108.88M | -101.32M |
| NetIncomeCommonStockholders | -86.62M | -98.43M | -108.88M | -101.32M |
| NetIncome | -86.62M | -98.43M | -108.88M | -101.32M |
| NetIncomeIncludingNoncontrollingInterests | -86.62M | -98.43M | -108.88M | -101.32M |
| NetIncomeContinuousOperations | -86.62M | -98.43M | -108.88M | -101.32M |
| TaxProvision | 0.00 | 4.23M | 0.00 | |
| PretaxIncome | -86.62M | -94.20M | -108.88M | -101.32M |
| OtherIncomeExpense | 1.76M | 2.83M | 2.58M | 1.26M |
| OtherNonOperatingIncomeExpenses | 4.16M | 2.83M | 2.58M | 2.49M |
| SpecialIncomeCharges | -2.40M | 0.00 | 0.00 | -1.23M |
| OtherSpecialCharges | 1.23M | |||
| WriteOff | 2.40M | 0.00 | ||
| ImpairmentOfCapitalAssets | 2.40M | 0.00 | ||
| NetNonOperatingInterestIncomeExpense | 11.90M | 10.88M | 5.67M | -1.85M |
| InterestExpenseNonOperating | 0.00 | 1.91M | ||
| InterestIncomeNonOperating | 11.90M | 10.88M | 5.67M | 59.00K |
| OperatingIncome | -100.28M | -107.91M | -117.14M | -100.73M |
| OperatingExpense | 122.89M | 142.06M | 136.37M | 102.05M |
| ResearchAndDevelopment | 94.53M | 109.69M | 105.62M | 80.33M |
| SellingGeneralAndAdministration | 28.36M | 32.37M | 30.75M | 21.73M |
| GeneralAndAdministrativeExpense | 28.36M | 32.37M | 30.75M | 21.73M |
| OtherGandA | 11.23M | 11.81M | 12.50M | 9.67M |
| SalariesAndWages | 17.12M | 20.57M | 18.24M | 12.06M |
| TotalRevenue | 22.60M | 34.16M | 19.23M | 1.32M |
| OperatingRevenue | 22.60M | 34.16M | 19.23M | 1.32M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 55.59M | 42.28M | 41.80M | 41.30M |
| ShareIssued | 55.59M | 42.28M | 41.80M | 41.30M |
| TotalDebt | 37.13M | 45.07M | 51.51M | 58.33M |
| TangibleBookValue | -45.53M | -77.19M | 112.00K | 96.87M |
| InvestedCapital | -45.53M | -77.19M | 112.00K | 96.87M |
| WorkingCapital | 182.61M | 181.75M | 296.19M | 410.87M |
| NetTangibleAssets | -45.53M | -77.19M | 112.00K | 96.87M |
| CapitalLeaseObligations | 37.13M | 45.07M | 51.51M | 58.33M |
| CommonStockEquity | -45.53M | -77.19M | 112.00K | 96.87M |
| TotalCapitalization | -45.53M | -77.19M | 112.00K | 96.87M |
| TotalEquityGrossMinorityInterest | -45.53M | -77.19M | 112.00K | 96.87M |
| StockholdersEquity | -45.53M | -77.19M | 112.00K | 96.87M |
| GainsLossesNotAffectingRetainedEarnings | 135.00K | -826.00K | -3.99M | -10.00K |
| OtherEquityAdjustments | 135.00K | -826.00K | -3.99M | -10.00K |
| RetainedEarnings | -558.18M | -471.56M | -373.14M | -264.26M |
| AdditionalPaidInCapital | 512.51M | 395.20M | 377.23M | 361.13M |
| CapitalStock | 6.00K | 4.00K | 4.00K | 4.00K |
| CommonStock | 6.00K | 4.00K | 4.00K | 4.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 329.51M | 363.11M | 404.77M | 422.90M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 262.52M | 304.67M | 349.57M | 374.21M |
| OtherNonCurrentLiabilities | 29.00K | 143.00K | ||
| NonCurrentDeferredLiabilities | 234.46M | 268.12M | 304.00M | 322.73M |
| NonCurrentDeferredRevenue | 234.46M | 268.12M | 304.00M | 322.73M |
| LongTermDebtAndCapitalLeaseObligation | 28.06M | 36.55M | 45.54M | 51.34M |
| LongTermCapitalLeaseObligation | 28.06M | 36.55M | 45.54M | 51.34M |
| CurrentLiabilities | 66.99M | 58.44M | 55.20M | 48.69M |
| OtherCurrentLiabilities | 1.00K | 36.00K | 318.00K | 392.00K |
| CurrentDeferredLiabilities | 45.61M | 34.55M | 32.82M | 28.32M |
| CurrentDeferredRevenue | 45.61M | 34.55M | 32.82M | 28.32M |
| CurrentDebtAndCapitalLeaseObligation | 9.07M | 8.52M | 5.97M | 6.99M |
| CurrentCapitalLeaseObligation | 9.07M | 8.52M | 5.97M | 6.99M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 4.74M | 4.35M | 4.74M | 5.60M |
| PayablesAndAccruedExpenses | 7.57M | 10.98M | 11.35M | 7.39M |
| CurrentAccruedExpenses | 3.79M | 4.05M | 5.94M | 3.57M |
| Payables | 3.79M | 6.93M | 5.41M | 3.82M |
| TotalTaxPayable | 0.00 | 674.00K | 0.00 | |
| IncomeTaxPayable | 0.00 | 674.00K | 0.00 | |
| AccountsPayable | 3.79M | 6.26M | 5.41M | 3.82M |
| TotalAssets | 283.98M | 285.92M | 404.88M | 519.77M |
| TotalNonCurrentAssets | 34.38M | 45.73M | 53.48M | 60.21M |
| OtherNonCurrentAssets | 1.78M | 2.82M | 4.09M | 4.13M |
| NetPPE | 32.60M | 42.91M | 49.40M | 56.08M |
| AccumulatedDepreciation | -15.08M | -12.02M | -8.61M | -5.33M |
| GrossPPE | 47.69M | 54.93M | 58.01M | 61.41M |
| Leases | 17.02M | 17.24M | 17.12M | 17.06M |
| OtherProperties | 7.12M | 6.80M | 5.88M | 4.92M |
| MachineryFurnitureEquipment | 906.00K | 930.00K | 915.00K | 915.00K |
| BuildingsAndImprovements | 22.64M | 29.96M | 34.09M | 38.52M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 249.60M | 240.18M | 351.40M | 459.56M |
| OtherCurrentAssets | 5.85M | 6.12M | 5.60M | 5.27M |
| PrepaidAssets | 5.27M | |||
| Receivables | 0.00 | 300.00M | ||
| AccountsReceivable | 0.00 | 300.00M | ||
| CashCashEquivalentsAndShortTermInvestments | 243.75M | 234.06M | 345.80M | 154.29M |
| OtherShortTermInvestments | 188.29M | 153.72M | 293.58M | 53.15M |
| CashAndCashEquivalents | 55.45M | 80.34M | 52.21M | 101.14M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -101.31M | -119.33M | 192.40M | -53.56M |
| RepaymentOfDebt | 0.00 | -21.20M | ||
| IssuanceOfDebt | 0.00 | |||
| IssuanceOfCapitalStock | 103.40M | 0.00 | 0.00 | 42.20M |
| CapitalExpenditure | -906.00K | -1.22M | -1.21M | -3.31M |
| InterestPaidSupplementalData | 0.00 | 1.72M | ||
| IncomeTaxPaidSupplementalData | 860.00K | 3.55M | 0.00 | |
| EndCashPosition | 57.16M | 82.04M | 53.92M | 102.87M |
| BeginningCashPosition | 82.04M | 53.92M | 102.87M | 94.53M |
| ChangesInCash | -24.88M | 28.12M | -48.95M | 8.34M |
| FinancingCashFlow | 105.43M | 1.78M | 1.76M | 22.42M |
| CashFlowFromContinuingFinancingActivities | 105.43M | 1.78M | 1.76M | 22.42M |
| NetOtherFinancingCharges | -585.00K | |||
| ProceedsFromStockOptionExercised | 2.61M | 1.78M | 1.76M | 1.42M |
| NetPreferredStockIssuance | 0.00 | |||
| PreferredStockIssuance | 0.00 | |||
| NetCommonStockIssuance | 103.40M | 0.00 | 0.00 | 42.20M |
| CommonStockIssuance | 103.40M | 0.00 | 0.00 | 42.20M |
| NetIssuancePaymentsOfDebt | 0.00 | -21.20M | ||
| NetLongTermDebtIssuance | 0.00 | -21.20M | ||
| LongTermDebtPayments | 0.00 | -21.20M | ||
| LongTermDebtIssuance | 0.00 | |||
| InvestingCashFlow | -29.90M | 144.45M | -244.32M | 36.17M |
| CashFlowFromContinuingInvestingActivities | -29.90M | 144.45M | -244.32M | 36.17M |
| NetInvestmentPurchaseAndSale | -29.00M | 145.67M | -243.11M | 39.49M |
| SaleOfInvestment | 232.47M | 219.57M | 166.23M | 139.47M |
| PurchaseOfInvestment | -261.47M | -73.90M | -409.35M | -99.98M |
| NetPPEPurchaseAndSale | -906.00K | -1.22M | -1.21M | -3.31M |
| SaleOfPPE | 0.00 | |||
| PurchaseOfPPE | -906.00K | -1.22M | -1.21M | -3.31M |
| OperatingCashFlow | -100.41M | -118.11M | 193.61M | -50.25M |
| CashFlowFromContinuingOperatingActivities | -100.41M | -118.11M | 193.61M | -50.25M |
| ChangeInWorkingCapital | -32.27M | -41.88M | 281.55M | 33.44M |
| ChangeInOtherWorkingCapital | -22.60M | -34.16M | -14.23M | 336.48M |
| ChangeInOtherCurrentLiabilities | -7.94M | -7.51M | -6.97M | -4.01M |
| ChangeInPayablesAndAccruedExpense | -3.04M | -951.00K | 3.06M | 2.79M |
| ChangeInAccruedExpense | -564.00K | -1.80M | 1.44M | 2.65M |
| ChangeInPayable | -2.48M | 846.00K | 1.61M | 135.00K |
| ChangeInAccountPayable | -2.48M | 846.00K | 1.61M | 135.00K |
| ChangeInPrepaidAssets | 1.32M | 741.00K | -307.00K | -1.81M |
| ChangeInReceivables | 0.00 | 300.00M | -300.00M | |
| ChangesInAccountReceivables | 300.00M | -300.00M | ||
| OtherNonCashItems | 5.68M | 5.21M | 4.58M | 4.61M |
| StockBasedCompensation | 11.89M | 16.19M | 14.34M | 8.38M |
| AssetImpairmentCharge | 2.40M | 0.00 | ||
| AmortizationOfSecurities | -4.61M | -2.65M | -1.29M | 179.00K |
| DepreciationAmortizationDepletion | 3.12M | 3.45M | 3.32M | 3.23M |
| DepreciationAndAmortization | 3.12M | 3.45M | 3.32M | 3.23M |
| Depreciation | 3.32M | 3.23M | ||
| OperatingGainsLosses | 3.00K | 6.00K | 1.23M | |
| GainLossOnSaleOfPPE | 0.00 | 3.00K | 6.00K | 0.00 |
| NetIncomeFromContinuingOperations | -86.62M | -98.43M | -108.88M | -101.32M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for FHTX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|